Skip to main content

Advertisement

SpringerLink
Log in

Post Transplant Lymphoproliferative Disorder

  • Review
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Posttransplant lymphoproliferative disorder is an extremely fatal complication arising in transplant recipients as a side effect of immunosuppression. PTLDs are seen after both solid organ and hematopoietic stem cell transplants though the incidence is much higher in the former. Primary Epstein–Barr virus (EBV) infection or reactivation due to a state of immune dysregulation along with intensity of immunosuppression used are of paramount importance in pathogenesis of PTLD. EBV associated PTLDs occur early in the post transplant period whereas late onset lymphomas are usually EBV negative. The uncontrolled B cell proliferation can create a spectrum of histological patterns from nondestructive lesions to destructive polymorphic or more aggressive monomorphic PTLDs. Early detection of seropositivity by serial monitoring in the recipient can prevent PTLD development by starting pre-emptive therapy. The mainstay treatment in established cases remains reduction of immunosuppression. Chemotherapeutic and immunomodulatory agents are added sequentially based on the type of PTLD and based on its response to initial therapy. Despite various treatment options available, the morbidity remains high and achieving state of disease remission without causing graft rejection can be quite challenging. Hence, a better understanding in pathobiology of EBV+ versus EBV− PTLDS may help prevent lymphomagenesis in transplant recipients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Doak PB, Montgomerie JZ, North JD, Smith F (1968) Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J 4:746–748

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Penn I, Hammond W, Brettschneider L, Starzl TE (1969) Malignant lymphomas in transplantation patients. Transpl Proc 1:106–112

    CAS  Google Scholar 

  3. Ghobrial IM, Habermann TM, Macon WR et al (2005) Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 79:244–247

    Article  PubMed  Google Scholar 

  4. Johnson LR, Nalesnik MA, Swerdlow SH (2006) Impact of Epstein–Barr virus in monomorphic B cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol 30(12):1604–1612

    Article  PubMed  Google Scholar 

  5. Nourse JP, Jones K, Gandhi MK (2011) Epstein–Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transpl 11(5):888–895

    Article  CAS  Google Scholar 

  6. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW (2009) Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 27(20):3354–3362

    Article  PubMed  Google Scholar 

  7. Taylor AL, Marcus R, Bradley JA (2005) Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56:155–167

    Article  PubMed  Google Scholar 

  8. Cockfield SM (2001) Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3:70–78

    Article  CAS  PubMed  Google Scholar 

  9. Bates WD, Gray DW, Dada MA et al (2003) Lymphoproliferative disorders in oxford renal transplant recipients. J Clin Pathol 56:439–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R et al (2001) Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19(3):772–778

    Article  CAS  PubMed  Google Scholar 

  11. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS et al (2005) Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 23(30):7574–7582

    Article  PubMed  Google Scholar 

  12. Dotti G, Fiocchi R, Motta T, Mammana C, Gotti E, Riva S et al (2002) Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 74(8):1095–1102

    Article  PubMed  Google Scholar 

  13. Buell JF, Gross TG, Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR et al (2005) Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transpl Proc 37(2):954–955

    Article  CAS  Google Scholar 

  14. Penn I, Porat G (1995) Central nervous system lymphomas in organ allograft recipients. Transplantation 59(2):240–244

    Article  CAS  PubMed  Google Scholar 

  15. Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative G (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group report. Cancer 116(4):863–870

    Article  PubMed  PubMed Central  Google Scholar 

  16. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B (1997) Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 10(3):136–145

    CAS  PubMed  Google Scholar 

  17. Caillard S, Lelong C, Pessione F, Moulin B, French PTLD Working Group (2006) Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transpl 6:2735–2742

    Article  CAS  Google Scholar 

  18. Oton AB, Wang H, Leleu X et al (2008) Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 49:1738–1744

    Article  CAS  PubMed  Google Scholar 

  19. Kinch A et al (2014) Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation. Am J Transpl 14:2838–2845

    Article  CAS  Google Scholar 

  20. Sanz J et al (2014) EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transpl 49:397–402

    Article  CAS  Google Scholar 

  21. Doycheva I, Amer S, Watt KD (2016) De novo malignancies after transplantation: risk and surveillance strategies. Med Clin North Am 100(3):551–567

    Article  PubMed  Google Scholar 

  22. Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348(17):1681–1691

    Article  PubMed  Google Scholar 

  23. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V (1996) Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transpl 10(3):248–255

    CAS  Google Scholar 

  24. Sundin M, Le Blanc K, Ringden O et al (2006) The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 91:1059–1067

    PubMed  Google Scholar 

  25. Landgren O, Gilbert ES, Rizzo JD et al (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992–5001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Juvonen E, Aalto SM, Tarkkanen J et al (2003) High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transpl 32:97–102

    Article  CAS  Google Scholar 

  27. Trofe J et al (2005) Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transpl 5:775–780

    Article  Google Scholar 

  28. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson I (2012) Impact of Epstein–Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transpl 27:2971–2979

    Article  Google Scholar 

  29. Allen U, Hébert D, Moore D, Dror Y, Wasfy S, the Canadian PTLD Survey Group—1998 (2001) Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipient, 1988–97: a Canadian multi-centre experience. Pediatr Transpl 5:198–203

  30. Opelz G, Dohler B (2004) Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transpl 4(2):222–230

    Article  Google Scholar 

  31. Lange A, Klimczak A, Dlubek D, Dybko J (2003) B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen. Transpl Proc 35(8):3093–3095

    Article  CAS  Google Scholar 

  32. Schubert S, Renner C, Hammer M et al (2008) Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transpl 27(1):100–105

    Article  Google Scholar 

  33. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80(9):1233–1243

    Article  CAS  PubMed  Google Scholar 

  34. Duvoux C, Pageaux GP, Vanlemmens C et al (2002) Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 74(8):1103–1109

    Article  PubMed  Google Scholar 

  35. Opelz G, Naujokat C, Daniel V, Terness P, Dohler B (2006) Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81(9):1227–1233

    Article  CAS  PubMed  Google Scholar 

  36. Krams SM, Martinez OM (2008) Epstein–Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transpl 13(6):563–568

    Article  Google Scholar 

  37. Cao S, Cox KL, Berquist W et al (1999) Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transpl 3(1):22–26

    Article  CAS  Google Scholar 

  38. Uhlin M et al (2014) Risk factors for Epstein–Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99:346–352

    Article  PubMed  PubMed Central  Google Scholar 

  39. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein–Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497–506

    Article  CAS  PubMed  Google Scholar 

  40. Langerak AW, Moreau E, van Gastel-Mol EJ, van der Burg M, van Dongen JJ (2002) Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool. Leukemia 16:1572–1573

    Article  CAS  PubMed  Google Scholar 

  41. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ (2003) Pathogenic roles for Epstein–Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol 45:1–36

    Article  PubMed  Google Scholar 

  42. Delecluse HJ, Bartnizke S, Hammerschmidt W, Bullerdiek J, Bornkamm GW (1993) Episomal and integrated copies of Epstein–Barr virus coexist in Burkitt lymphoma cell lines. J Virol 67:1292–1299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ohshima K, Suzumiya J, Kanda M, Kato A, Kikuchi M (1998) Integrated and episomal forms of Epstein–Barr virus (EBV) in EBV associated disease. Cancer Lett 122:43–50

    Article  CAS  PubMed  Google Scholar 

  44. Reisinger J, Rumpler S, Lion T, Ambros PF (2006) Visualization of episomal and integrated Epstein–Barr virus DNA by fiber fluorescence in situ hybridization. Int J Cancer 118:1603–1608

    Article  CAS  PubMed  Google Scholar 

  45. Chaganti S et al (2009) Epstein–Barr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood 113:6372–6381

    Article  PubMed  CAS  Google Scholar 

  46. Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A (2015) Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett 369(1):37–44

    Article  CAS  PubMed  Google Scholar 

  47. Luskin MR, Heil DS, Tan KS et al (2015) The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transpl 15(10):2665–2673

    Article  CAS  Google Scholar 

  48. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K (1994) Isolation of Epstein–Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt’s lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68(9):6069–6073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ambinder RF (2000) Gammaherpesviruses and “hit-and-run” oncogenesis. Am J Pathol 156(1):1–3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Capello D, Rossi D, Gaidano G (2005) Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 23(2):61–67

    Article  PubMed  Google Scholar 

  51. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH (2000) Epstein–Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24(3):375–385

    Article  CAS  PubMed  Google Scholar 

  52. Rinaldi A, Capello D, Scandurra M et al (2010) Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol 149(4):569–577

    Article  CAS  PubMed  Google Scholar 

  53. Swerdlow SH (2017) World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 5th, Lyon, France: International Agency for Research on Cancer. International Agency for Research on Cancer

  54. Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G et al (2010) Diagnosis of posttransplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS Guidelines. Br J Haematol 149(5):675–692

    Article  PubMed  Google Scholar 

  55. Carpentier L, Tapiero B, Alvarez F et al (2003) Epstein–Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis 188:1853–1864

    Article  PubMed  Google Scholar 

  56. Young L, Alfieri C, Hennessy K et al (1989) Expression of Epstein–Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N EngI J Med 321:1080–1085

    Article  CAS  Google Scholar 

  57. Fanaian N, Cohen C, Waldrop S et al (2009) EBER: automated in situ hybridization (ISH) vs. manual ISH and immunohistochemistry (IHC) for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol 12:195–199

    Article  PubMed  Google Scholar 

  58. Hayden RT, Hokanson KM, Pounds SB et al (2008) Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein–Barr virus. J Clin Microbiol 46:157–163

    Article  CAS  PubMed  Google Scholar 

  59. Preiksaitis JK, Pang XL, Fox JD et al (2009) Inter-laboratory comparison of Epstein–Barr virus (EBV) viral load assays. Am J Transpl 9:269–279

    Article  CAS  Google Scholar 

  60. Hakim H, Gibson C, Pan J et al (2007) Comparison of various blood compartments and reporting units for the detection and quantification of Epstein–Barr virus (EBV) in peripheral blood. J Clin Microbiol 45:2151–2155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. De Paoli P, Pratesi C, Bortolin MT (2007) The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol 133:809–815

    Article  PubMed  CAS  Google Scholar 

  62. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM et al (2005) Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 46(2):191–196

    Article  CAS  PubMed  Google Scholar 

  63. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86(9):3333–3340

    Article  CAS  PubMed  Google Scholar 

  64. Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S et al (2011) Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transpl 11(2):336–347

    Article  CAS  Google Scholar 

  65. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM et al (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28(6):1038–1046

    Article  PubMed  PubMed Central  Google Scholar 

  66. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P et al (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13(2):196–206

    Article  CAS  PubMed  Google Scholar 

  67. Ramanarayanan Jeyanthi, Krishnan Ganapathy S, Czuczman Myron S, Hernandez-Ilizaliturri Francisco J (2007) Efficacy and safety of rituximab in post transplant lymphoproliferative disorders (PTLD): pooled analysis and review of literature. Blood 110:1084

    Article  Google Scholar 

  68. Evens AM, David KA, Helenowski I et al (2010) Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 28:1038–1046

    Article  PubMed  PubMed Central  Google Scholar 

  69. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al (2007) Allogeneic cytotoxic T cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110(4):1123–1131

    Article  CAS  Google Scholar 

  70. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549–1555

    Article  CAS  Google Scholar 

  71. Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al (2000) Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95(3):807–814

    Article  CAS  PubMed  Google Scholar 

  72. Gottschalk Stephen, Rooney Cliona (2015) Adoptive T-cell immunotherapy. Curr Top Microbiol Immunol 391:427–454

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A et al (2001) Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clinical trial. Blood 97(6):1590–1597

    Article  CAS  PubMed  Google Scholar 

  74. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC (1998) Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66(12):1770–1779

    Article  CAS  PubMed  Google Scholar 

  75. Komrokji RS, Oliva JL, Zand M, Felgar R, Abboud CN (2005) Mini-BEAM and autologous hematopoietic stem cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol 79(3):211–215

    Article  PubMed  Google Scholar 

  76. Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P et al (2008) Successful treatment of a child with late-onset T cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer 50(3):667–670

    Article  PubMed  Google Scholar 

  77. Cavaliere R, Petroni G, Lopes MB, Schiff D, The International Primary Central Nervous System Lymphoma Collaborative Group (2010) Primary central nervous system post-transplantation lymphoproliferative disorder. Cancer 116:863–870

    Article  PubMed  PubMed Central  Google Scholar 

  78. Patrick A, Wee A, Hedderman A, Wilson D, Weiss J, Govani M (2011) High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neuro Oncol 103:739–743

    Article  CAS  Google Scholar 

  79. Daan D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378:549–562

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Laboratory Science and Molecular Medicine, Army Hospital (Research and Referral), New Delhi, India

    Devika Gupta & Tathagata Chatterjee

  2. Department of Nephrology, Army Hospital (Research and Referral), New Delhi, India

    Satish Mendonca

  3. Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India

    Sushmita Chakraborty

Authors
  1. Devika Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satish Mendonca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sushmita Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tathagata Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tathagata Chatterjee.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gupta, D., Mendonca, S., Chakraborty, S. et al. Post Transplant Lymphoproliferative Disorder. Indian J Hematol Blood Transfus 36, 229–237 (2020). https://doi.org/10.1007/s12288-019-01182-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01182-x

Keywords

Search

Navigation